Burns Matteson Capital Management LLC Acquires New Holdings in Ascendis Pharma A/S $ASND

Burns Matteson Capital Management LLC bought a new position in shares of Ascendis Pharma A/S (NASDAQ:ASND) in the 3rd quarter, HoldingsChannel.com reports. The fund bought 2,459 shares of the biotechnology company’s stock, valued at approximately $560,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ASND. Caitong International Asset Management Co. Ltd purchased a new stake in Ascendis Pharma A/S in the fourth quarter valued at $42,000. Allworth Financial LP grew its holdings in shares of Ascendis Pharma A/S by 103.4% during the 2nd quarter. Allworth Financial LP now owns 240 shares of the biotechnology company’s stock worth $64,000 after purchasing an additional 122 shares during the period. EverSource Wealth Advisors LLC grew its holdings in shares of Ascendis Pharma A/S by 34.0% during the 1st quarter. EverSource Wealth Advisors LLC now owns 272 shares of the biotechnology company’s stock worth $62,000 after purchasing an additional 69 shares during the period. Parallel Advisors LLC grew its holdings in shares of Ascendis Pharma A/S by 94.9% during the 1st quarter. Parallel Advisors LLC now owns 304 shares of the biotechnology company’s stock worth $70,000 after purchasing an additional 148 shares during the period. Finally, IFP Advisors Inc increased its position in shares of Ascendis Pharma A/S by 3,491.7% during the 2nd quarter. IFP Advisors Inc now owns 431 shares of the biotechnology company’s stock worth $115,000 after purchasing an additional 419 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on ASND shares. Jefferies Financial Group reduced their price objective on shares of Ascendis Pharma A/S from $333.00 to $330.00 and set a “buy” rating on the stock in a report on Monday, August 31st. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $300.00 target price on shares of Ascendis Pharma A/S in a research note on Friday, September 25th. HC Wainwright set a $344.00 target price on shares of Ascendis Pharma A/S in a research note on Thursday, September 10th. Bank of America dropped their price target on shares of Ascendis Pharma A/S from $306.00 to $304.00 and set a “buy” rating for the company in a research report on Monday, August 31st. Finally, Wedbush reissued an “outperform” rating and issued a $327.00 price target on shares of Ascendis Pharma A/S in a research note on Tuesday, September 1st. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $309.26.

Insider Transactions at Ascendis Pharma A/S

In other Ascendis Pharma A/S news, Director Jean-Jacques Bienaimé purchased 2,000 shares of Ascendis Pharma A/S stock in a transaction dated Friday, August 14th. The shares were acquired at an average price of $246.33 per share, with a total value of $492,660.00. Following the completion of the transaction, the director owned 2,900 shares of the company’s stock, valued at $714,357. This trade represents a 222.22% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Mads Bodenhoff sold 3,000 shares of the stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $270.19, for a total transaction of $810,570.00. Following the sale, the senior vice president directly owned 3,000 shares in the company, valued at $810,570. This represents a 50.00% decrease in their position. The SEC filing for this sale provides additional information. 40.00% of the stock is owned by corporate insiders.

Ascendis Pharma A/S Price Performance

ASND opened at $225.25 on Friday. The stock’s 50-day moving average price is $244.45 and its 200 day moving average price is $242.40. Ascendis Pharma A/S has a 12-month low of $186.05 and a 12-month high of $282.15. The company has a current ratio of 2.99, a quick ratio of 2.32 and a debt-to-equity ratio of 0.27. The firm has a market cap of $14.05 billion, a price-to-earnings ratio of 17.47 and a beta of 0.38.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its earnings results on Friday, August 14th. The biotechnology company reported $1.03 EPS for the quarter, missing analysts’ consensus estimates of $1.71 by ($0.68). The firm had revenue of $387.22 million for the quarter, compared to analysts’ expectations of $376.75 million. Ascendis Pharma A/S had a net margin of 70.99% and a return on equity of 32.54%. As a group, sell-side analysts expect that Ascendis Pharma A/S will post 3.55 earnings per share for the current year.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S is a biopharmaceutical company focused on developing therapies for rare diseases, particularly in endocrinology. The company uses its proprietary TransCon technology platform to design medicines intended to provide sustained release of therapeutic compounds and potentially improve treatment convenience and patient outcomes.

Ascendis Pharma’s marketed products include Skytrofa (lonapegsomatropin-tcgb), a once-weekly growth hormone treatment for children with growth hormone deficiency, and Yorvipath (palopegteriparatide), a parathyroid hormone replacement therapy for adults with hypoparathyroidism.